UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Case Series of MET Exon 14 Skipping Mutation-positive Non–Small Cell Lung Cancers and Response to Crizotinib

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.239-239

2017

Volltextzugriff (PDF)

P35.19 The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S428-S428

2021

Volltextzugriff (PDF)

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.410-415

2012

Volltextzugriff (PDF)

CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S41-S42

2016

Volltextzugriff (PDF)

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S52-S53

2014

Volltextzugriff (PDF)

Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S75-S75

2014

Volltextzugriff (PDF)

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S178-S178

2015

Volltextzugriff (PDF)

Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S812-S812

2014

Volltextzugriff (PDF)

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.199-199

2014

Volltextzugriff (PDF)

Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S60-S61

2014

Volltextzugriff (PDF)

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S38

2014

Volltextzugriff (PDF)

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Annals of oncology, 2023-10, Vol.34 (10), p.907-919

2023

Volltextzugriff (PDF)

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S36-S36

2014

Volltextzugriff (PDF)

Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors

International journal of radiation oncology, biology, physics, 2019-05, Vol.104 (1), p.239-239

2019

Volltextzugriff (PDF)

MA02.06 Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S102-S103

2023

Volltextzugriff (PDF)

P76.70 Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S619-S619

2021

Volltextzugriff (PDF)

CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e110-e110

2023

Volltextzugriff (PDF)

P4.04D.08 Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the U.S. SEER Cancer Registries

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S375-S375

2024

Volltextzugriff (PDF)

P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S196-S197

2024

Volltextzugriff (PDF)

A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.S60-S60

2024

Volltextzugriff (PDF)

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e420-e421

2021

Volltextzugriff (PDF)

OA17.06 Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S49-S49

2024

Volltextzugriff (PDF)

OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S8-S9

2024

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.376-381

2010

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(15)
Radiology
(11)
Life Sciences & Biomedicine
(8)
Oncology
(8)
Science & Technology
(8)
Humans
(7)
Aged
(5)
Female
(5)
Middle Aged
(5)
Nsclc
(5)
Adult
(4)
Male
(4)
Biological And Medical Sciences
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Lung Neoplasms - Drug Therapy
(3)
Medical Sciences
(3)
Original
(3)
Antineoplastic Agents
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Carcinoma, Non-Small-Cell Lung - Mortality
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

International Journal Of Radiation Oncology, Biology, Physics
(29)
Journal Of Thoracic Oncology
(16)
Annals Of Oncology
(9)
European Journal Of Cancer Supplements
(2)
Clinical Lung Cancer
(1)
European Journal Of Cancer
(1)
Lung Cancer
(1)

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Case Series of MET Exon 14 Skipping Mutation-positive Non–Small Cell Lung Cancers and Response to Crizotinib

P35.19 The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors

Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial

Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors

MA02.06 Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening

P76.70 Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC

P4.04D.08 Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the U.S. SEER Cancer Registries

P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC

A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation

OA17.06 Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities

OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Suchergebnisse filtern